Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s...
March 05 2021 - 8:30AM
Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF)
(the "
Company" or "
Claritas")
today announced the addition of Professor Salvatore Cuzzocrea,
Ph.D. as an independent member of the Company’s board of directors
(the “Board of Directors”), effective immediately.
Dr. Cuzzocrea is an acknowledged expert in the science and
clinical use of nitric oxide therapy, and his appointment to the
Board of Directors will position the Company as a leader in the
field of nitric oxide therapeutics.
“We are delighted to add Dr. Cuzzocrea to the
Company’s Board of Directors,” stated Robert Farrell, President and
CEO. “We are eager to begin work with Dr. Cuzzocrea on development
of R-107, our proprietary nitric oxide releasing compound that is
being developed as a treatment for coronavirus, vaccine-resistant
COVID-19, and other viral infections. With his deep experience and
knowledge regarding nitric oxide and R-107, he will be a strong
strategic resource for Claritas. We look forward to the
contributions he will make.”
Nitric oxide has been demonstrated to be
effective against a wide variety of viruses. Nevertheless, nitric
oxide has not been developed as an antiviral agent due to the fact
that it is a gas that must be administered by inhalation therapy,
which requires special inhalation equipment and administration by
trained respiratory therapists. R-107 is a liquid, nitric
oxide releasing compound designed to overcome these issues. R-107
can be easily administered orally as a capsule, or nasally through
use of a nasal spray, or by injection. Claritas will not only
develop R-107 as a therapy for vaccine-resistant COVID-9 infection,
but also as a broad-spectrum antiviral drug for the treatment and
possible prevention of future viral outbreaks, including viruses
that cause influenza and the common cold.
Dr. Cuzzocrea, the former President of the
European Shock Society, is an internationally renowned authority
and leader on the biology and pathophysiology of nitric oxide.
He currently serves in numerous leadership roles at the
University of Messina in Sicily, including Director of Scientific
Research, Director of the Department of Chemical, Biological,
Pharmaceutical and Environmental Sciences, Director of the Oncology
Unit at the University Hospital of Messina, and Full Professor
of Pharmacology at the University’s School of Medicine.
Dr. Cuzzocrea has been awarded honorary Professorships in
Pharmacology at the University of Manchester and Saint
Louis University, was elected a Fellow of the British
Pharmacological Society, and has been appointed as an Honorary
Lecturer in Pharmacology at the Department of Experimental
Medicine and Nephrology at The William Harvey Institute at St.
Bartholomew’s and Royal London School of Medicine and
Dentistry. In 2020, Professor Cuzzocrea was elected
Vice-President of the Board of the Conference of Rectors of all
Italian universities.
Dr. Cuzzocrea received his
undergraduate and graduate medical education at the University of
Messina, followed by doctoral studies at Cincinnati Children’s
Hospital Medical Center and the William Harvey Institute in London.
He is the author of more than 759 peer-reviewed publications and
books, and is an international leader in the fields of
autoimmunity, inflammation, toxic inhalational lung injury, and
neurodegenerative disorders. Dr. Cuzzocrea’s research
interests include the role of nitric oxide in the
pathophysiology and treatment of pulmonary inflammation and
cytokine storm associated acute lung injury, and
the identification of new potential pharmacological targets
for nitric oxide in autoimmune and inflammatory diseases.
Dr. Cuzzocrea brings expert knowledge of
R-107 to Claritas, having carried out more than 40 studies of this
molecule in the treatment of experimental models of acute lung
injury, pulmonary arterial hypertension, wound healing,
ischemia-reperfusion injury, and multiple organ failure in sepsis
and endotoxic shock. Dr. Cuzzocrea is an authority also
on the biological mechanisms of cytokine-storm induced acute lung
injury, and thus is ideally positioned to understand the
pathophysiology of COVID-19 disease and its amelioration by
supplemental provision of nitric oxide by administration of
R-107.
About Claritas
PharmaceuticalsClaritas Pharmaceuticals, Inc. is a
clinical stage biopharmaceutical company focused on developing and
commercializing therapies for patients with significant unmet
medical needs. Claritas focuses on areas of unmet medical need, and
leverages its expertise to find solutions that will improve health
outcomes and dramatically improve people's lives.
- Website
Home: https://claritaspharma.com/
- News and
Insights: https://claritaspharma.com/news/
-
Investors: https://claritaspharma.com/investors
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of its product candidate pipeline,
planned clinical trials, regulatory approval prospects,
intellectual property objectives, and other statements containing
the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "continue", "estimate", "forecasts" and other
similar expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risk that future
clinical studies may not proceed as expected or may produce
unfavorable results. Claritas undertakes no obligation to comment
on analyses, expectations or statements made by third parties, its
securities, or financial or operating results (as applicable).
Although Claritas believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Claritas’ control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Claritas disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact InformationRobert
FarrellPresident, CEO(888) 861-2008info@claritaspharma.com
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From May 2024 to Jun 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Jun 2023 to Jun 2024